BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29507076)

  • 41. The Genomic Landscape of PAX5, IKZF1, and CDKN2A/B Alterations in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Ou Z; Sherer M; Casey J; Bakos HA; Vitullo K; Hu J; Friehling E; Gollin SM; Surti U; Yatsenko SA
    Cytogenet Genome Res; 2016; 150(3-4):242-252. PubMed ID: 28214896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
    Moorman AV; Barretta E; Butler ER; Ward EJ; Twentyman K; Kirkwood AA; Enshaei A; Schwab C; Creasey T; Leongamornlert D; Papaemmanuil E; Patrick P; Clifton-Hadley L; Patel B; Menne T; McMillan AK; Harrison CJ; Rowntree CJ; Marks DI; Fielding AK
    Leukemia; 2022 Mar; 36(3):625-636. PubMed ID: 34657128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
    Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
    Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
    Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
    JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence and prognostic significance of IKZF1 deletion in paediatric acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Srinivasan S; Ramanathan S; Kumar S; Peyam S; Radhakrishnan V
    Ann Hematol; 2023 Aug; 102(8):2165-2179. PubMed ID: 37154889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan.
    Hsu YC; Yu CH; Chen YM; Roberts KG; Ni YL; Lin KH; Jou ST; Lu MY; Chen SH; Wu KH; Chang HH; Lin DT; Lin SW; Lin ZS; Chiu WT; Chang CC; Ho BC; Mullighan CG; Yu SL; Yang YL
    Sci Rep; 2021 Mar; 11(1):5802. PubMed ID: 33707599
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical value of RAG1 expression and IKZF1 deletions in Philadelphia negative pediatric B cell precursor acute lymphoblastic leukemia.
    Aref S; Khaled N; Menshawy NE; Sabry M; Agder MA
    Pediatr Hematol Oncol; 2020 Aug; 37(5):380-389. PubMed ID: 32644850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols.
    Ofverholm I; Tran AN; Heyman M; Zachariadis V; Nordenskjöld M; Nordgren A; Barbany G
    Leukemia; 2013 Sep; 27(9):1936-9. PubMed ID: 23538749
    [No Abstract]   [Full Text] [Related]  

  • 50. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.
    Caye A; Beldjord K; Mass-Malo K; Drunat S; Soulier J; Gandemer V; Baruchel A; Bertrand Y; Cavé H; Clappier E
    Haematologica; 2013 Apr; 98(4):597-601. PubMed ID: 23065506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
    Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
    Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.
    Ruiz-Delgado GJ; Cantero-Fortiz Y; León-Peña AA; León-González M; Nuñez-Cortés AK; Ruiz-Argüelles GJ
    Rev Invest Clin; 2016; 68(4):210-4. PubMed ID: 27623040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss-of-function but not dominant-negative intragenic
    Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
    Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
    Norvilas R; Dirse V; Semaskeviciene R; Mickeviciute O; Gineikiene E; Stoskus M; Vaitkeviciene G; Rascon J; Griskevicius L
    BMC Cancer; 2021 Mar; 21(1):326. PubMed ID: 33781217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
    Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
    Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
    Gupta SK; Bakhshi S; Kumar L; Seth R; Kumar R
    Leuk Res; 2016 Feb; 41():7-11. PubMed ID: 26704074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
    Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
    Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
    Tomoyasu C; Imamura T; Tomii T; Yano M; Asai D; Goto H; Shimada A; Sanada M; Iwamoto S; Takita J; Minegishi M; Inukai T; Sugita K; Hosoi H
    Int J Hematol; 2018 Sep; 108(3):312-318. PubMed ID: 29786757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-microarray in high-risk Australian AIEOP-BFM B-cell acute lymphoblastic leukaemia cohort.
    Berry NK; Scott RJ; Sutton R; Law T; Trahair TN; Dalla-Pozza L; Ritchie P; Barbaric D; Enjeti AK
    Cancer Genet; 2020 Apr; 242():8-14. PubMed ID: 32058318
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
    Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.